Niagen Bioscience (NAGE) Asset Utilization Ratio (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Asset Utilization Ratio of 1.18 for Q1 2026, down 18.09% year-over-year from 1.44 in Q1 2025, and down 6.62% quarter-over-quarter from 1.27 in Q4 2025.
Niagen Bioscience (NAGE) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Asset Utilization Ratio for 14 consecutive years, with 1.18 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 18.09% year-over-year to 1.18; the TTM figure through Mar 2026 stood at 1.18 (down 18.09% YoY), while the FY2025 annual figure was 1.48, down 8.32% from the prior year.
- Asset Utilization Ratio eased to 1.18 in Q1 2026 per NAGE's latest filing, from 1.27 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1.66 in Q3 2024 and bottomed at 1.18 in Q1 2026.
- Historically, Asset Utilization Ratio has averaged 1.44 across 5 years, with a median of 1.45 in 2022.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 44.59% — and 2025, when it decreased 20.72%.
- Niagen Bioscience's Asset Utilization Ratio stood at 1.45 in 2022, then gained by 6.66% to 1.54 in 2023, then grew by 3.56% to 1.6 in 2024, then retreated by 20.72% to 1.27 in 2025, then fell by 6.62% to 1.18 in 2026.
- Business Quant data shows NAGE's Asset Utilization Ratio at 1.18 in Q1 2026, 1.27 in Q4 2025, and 1.32 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 1.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 |
| Mar 31, 2026 | 1.18 |
| Dec 31, 2025 | 1.27 |
| Sep 30, 2025 | 1.32 |
| Jun 30, 2025 | 1.35 |
| Mar 31, 2025 | 1.44 |
| Dec 31, 2024 | 1.60 |
| Sep 30, 2024 | 1.66 |
| Jun 30, 2024 | 1.58 |
| Mar 31, 2024 | 1.53 |
| Dec 31, 2023 | 1.54 |
| Sep 30, 2023 | 1.56 |
| Jun 30, 2023 | 1.51 |
| Mar 31, 2023 | 1.43 |
| Dec 31, 2022 | 1.45 |
| Sep 30, 2022 | 1.49 |
| Jun 30, 2022 | 1.39 |
| Mar 31, 2022 | 1.26 |
| Dec 31, 2021 | 1.14 |
| Sep 30, 2021 | 1.03 |